Drugs

, Volume 34, Supplement 3, pp 132–135 | Cite as

Aspects on the Benefit-Risk Balance of Felodipine in Hypertension

  • Dag Elmfeldt
  • S. Westerling
Section 3: Felodipine in Hypertension

Summary

This review attempts to evaluate the benefit-risk balance of felodipine in the treatment of hypertension. Known positive and negative properties of felodipine are considered. Although accurate benefit-risk statements may be difficult even for old, well-established drugs it is concluded that felodipine appears to be an effective and well tolerated new antihypertensive drug. The reduction in blood pressure during felodipine treatment has been superior to that seen with established antihypertensive drugs in controlled studies.

Keywords

Nifedipine Prazosin Felodipine Adverse Drug Event Minoxidil 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bencini PL, Crosti C, Sala F, Montagnino G, Tarantino A, et al. Gingival hyperplasia by nifedipine. Report of a case. Acta Derm Venereol 65: 362–365, 1985PubMedGoogle Scholar
  2. Borgmästers H, Forsén B, Tuomilehto J, Hellobø R, Walle PO, et al. Felodipine versus hydrochlorothiazide as an addition to a β-blocker in the treatment of hypertension. Drugs 34(Suppl. 3): 136–138, 1987CrossRefGoogle Scholar
  3. Culling W, Ruttley MSM, Sheridan DJ. Acute haemodynamic effects of felodipine during beta-blockade in patients with coronary artery disease. British Heart Journal 52: 431–434, 1984PubMedCrossRefGoogle Scholar
  4. Edgar B, Bengtsson B, Elmfeldt D, Lundborg P, Nyberg G, et al. Acute diuretic/natriuretic properties of felodipine in man. Drugs 29(Suppl. 2): 176–184, 1985PubMedCrossRefGoogle Scholar
  5. Gustafsson D. Microvascular mechanisms involved in calcium antagonist oedema formation. Journal of Cardiovascular Pharmacology 10(Suppl. 1): S121–S131, 1987PubMedCrossRefGoogle Scholar
  6. Jackson B, Morgan TO, Gibson J, Anderson A. Felodipine versus prazosin as an addition to a β-blocker in the treatment of essential hypertension: the Australian multicentre study. Drugs 34(Suppl. 3): 109–119, 1987PubMedCrossRefGoogle Scholar
  7. Jones CR, Rae AP, Been M, de Vane JP, Jamieson RR, et al. Electrophysiological effects of felodipine in combination with metoprolol. Drugs 29(Suppl. 2): 81–86, 1985PubMedCrossRefGoogle Scholar
  8. Lederman D, Lumerman H, Ruuben S, Freedman PD, Flushing NY. Gingival hyperplasia associated with nifedipine therapy. Report of a case. Oral Surgery, Oral Medicine and Oral Pathology 57: 620–622, 1984Google Scholar
  9. Ljung B. Vascular selectivity of felodipine. Drugs 29(Suppl. 2): 46–58, 1985PubMedCrossRefGoogle Scholar
  10. Maclean D (Co-operative Study Group). Felodipine vs hydralazine: a controlled trial as third line therapy in hypertension. British Journal of Clinical Pharmacology 21: 621–626, 1986CrossRefGoogle Scholar
  11. Muir AL, Wathen CG, Hannan WJ. Effects of felodipine on resistance and capacitance vessels in patients with essential hypertension. Drugs 29(Suppl. 2): 59–65, 1985PubMedCrossRefGoogle Scholar
  12. Ramon Y, Behar S, Kishon Y, Engelberg IS. Gingival hyperplasia caused by nifedipine — a preliminary report. International Journal of Cardiology 5: 195–204, 1984PubMedCrossRefGoogle Scholar
  13. Sluiter HE, Huysmans FThM, Thein ThA, Van Lier HJJ, Koene RAP. Haemodynamic, hormonal and diuretic effects of felodipine in healthy normotensive volunteers. Drugs 29(Suppl. 2): 26–35, 1985PubMedCrossRefGoogle Scholar
  14. Swedish Multicentre Study Group. Can standard triple treatment of hypertension be replaced by the combination of felodipine and a β-blocker? Journal of Hypertension 4(Suppl. 5): 446–447, 1986Google Scholar
  15. Wathen CG, MacLeod D, Tucker L, Muir AL. Felodipine as a replacement for minoxidil in the treatment of severe hypertension. European Heart Journal 7: 893–897, 1986PubMedGoogle Scholar

Copyright information

© ADIS Press Limited 1987

Authors and Affiliations

  • Dag Elmfeldt
    • 1
  • S. Westerling
    • 1
  1. 1.Medical Department, Cardiovascular ResearchAB HässleMölndalSweden

Personalised recommendations